`Tagon

Description

Tagon 150mg Tablet

Generic Name: Ranitidine

Manufacturer: Apex Pharmaceuticals Pvt. Ltd.

Pack Size: 10 tablets

Retail Price: 1.50 NPR

Indications:

Tagon Tablet (Ranitidine) is used for the treatment and prevention of various gastrointestinal conditions, including:

• Dyspepsia (indigestion)
• H. pylori infection (in combination with other medications)
• Benign gastric and duodenal ulceration
• Gastro-oesophageal reflux disease (GERD)
• Acid aspiration during general anesthesia (prophylaxis)
• Prophylaxis during NSAID treatment (to prevent ulcers)
• Stress ulceration of the upper gastrointestinal tract
• Zollinger-Ellison syndrome (a condition causing excessive stomach acid)
• Erosive oesophagitis

Dosage and Administration:

Tagon can be taken with or without food.

Adult Dose (Oral):

• Benign gastric and duodenal ulceration:
  • Initial: 300 mg once daily at bedtime or 150 mg twice daily for 4-8 weeks. For duodenal ulcers, 300 mg twice daily for 4 weeks may be used for improved healing.
  • Maintenance: 150 mg once daily at bedtime.
  • Maximum: 300 mg twice daily.
• Hypersecretory conditions:
  • Initial: 150 mg twice or three times daily, increased if needed.
  • Maximum: 6 g daily.
• Gastro-oesophageal reflux disease (GERD):
  • 150 mg twice daily or 300 mg at bedtime for up to 8 weeks. In severe cases, dosage may be increased to 150 mg four times daily for 12 weeks.
• Dyspepsia:
  • Chronic episodic: 150 mg twice daily for up to 6 weeks.
  • Short-term symptomatic relief: 75 mg, repeated if necessary up to 4 doses daily. Maximum duration of continuous use at one time: 2 weeks.
• Erosive oesophagitis: 150 mg four times daily.
  • Maintenance: 150 mg twice daily.
• NSAID-associated ulceration:
  • Treatment: 150 mg twice daily or 300 mg at bedtime for 8-12 weeks.
  • Prevention: 150 mg twice daily.

Hepatic Impairment: Dosage adjustment is generally not necessary.

Child Dose (Oral):

• Benign gastric and duodenal ulceration:
  • 1 month to 16 years: 4-8 mg/kg daily in 2 divided doses.
  • Maximum: 300 mg/day.
  • Treatment duration: 4-8 weeks.
  • Maintenance: 2-4 mg/kg once daily.
  • Maximum: 150 mg/day.
• Gastro-oesophageal reflux disease (GERD):
  • 1 month to 16 years: 5-10 mg/kg daily in 2 divided doses.
  • Maximum: 300 mg/day.
• Erosive oesophagitis:
  • 1 month to 16 years: 5-10 mg/kg daily in 2 divided doses.
  • Maximum: 600 mg/day.

Renal Dose:

• Oral:
  • Creatinine Clearance (CrCl) < 50 mL/min: 150 mg once daily at bedtime. Adjust dose cautiously if necessary.
• Parenteral (IV): Individual doses may be reduced to 25 mg.

IV Administration:

• Direct injection: 50 mg diluted to at least 20 mL with compatible IV infusion fluid and given over at least 5 minutes (4 mL/min).
• Intermittent infusion: 50 mg added to at least 100 mL of compatible IV solution and infused over 15-20 minutes.
• Continuous infusion: 150 mg diluted in 250 mL of IV fluid and infused at 6.25 mg/hr for 24 hours.

Contraindications:

• Porphyria

Precautions:

• Before initiating therapy, the possibility of malignancy should be ruled out, as Ranitidine may mask symptoms and delay the diagnosis of gastric malignancy.
• Use with caution in patients with difficulty swallowing.
• Use with caution in patients with renal and hepatic impairment.
• Pregnancy and Lactation: Drug crosses into breast milk. Discontinue the drug or use with caution after considering the benefits and risks.

Interactions:

• Propantheline bromide may delay absorption and increase peak serum concentration of Ranitidine.
• Ranitidine minimally inhibits the hepatic metabolism of coumarin anticoagulants, theophylline, diazepam, and propranolol.
• May alter the absorption of pH-dependent drugs (e.g., ketoconazole, midazolam, glipizide).
• Antacids may reduce the bioavailability of Ranitidine.

Adverse Effects:

Common (1-10%):

• Headache (3%)

Less Common (<1%):

• Abdominal pain, agitation, alopecia, confusion, constipation, diarrhea, dizziness, hypersensitivity reaction, nausea, vomiting.

Frequency Not Defined (Rare):

• Anemia, necrotizing enterocolitis in fetus or newborn, pancreatitis, thrombocytopenia, pancytopenia, agranulocytosis, acquired immune hemolytic anemia, arthralgia, myalgia.

Potentially Fatal:

• Anaphylaxis, severe hypersensitivity reactions.

Mechanism of Action:

Ranitidine competitively blocks histamine at the H2-receptors located on the gastric parietal cells. This action inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin levels.

Note: This information on Tagon Tablet is provided for general knowledge and is not intended for diagnosis, medical advice, or treatment. It is not a substitute for the exercise of professional medical judgment. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.